| INTRODUCTION
Gastro-oesophageal reflux disease (GERD) is a prevalent digestive disease that results from reflux of gastric contents into the oesophagus. 1, 2 The prevalence of GERD in East Asian countries is increasing, and is reported to be 4.5%-15.7% 3, 4 Population-based studies have
shown that the prevalence of symptom-based GERD in East Asia was 5.2%-8.5% from 2005 to 2010. According to the Korean National Health Insurance claim, data also show that the prevalence of GERD in Korea is increasing rapidly from 4.6% to 7.3% between 2005 and 2008. 5, 6 The spectrum of GERD includes erosive oesophagitis (EE) and nonerosive reflux disease (NERD). EE is characterised by the presence of oesophageal mucosal erosions induced by the reflux of gastric contents from the stomach, which can be diagnosed by endoscopy. Currently, proton-pump inhibitors (PPIs) are the first-line drug for treating EE and controlling symptoms. 7 Studies in patients with EE have shown high healing rates (88%-96%) after 8-week treatment with a PPI once daily. [8] [9] [10] However, some patients may have endoscopic evidence of oesophagitis and/or reflux symptoms despite PPI therapy. [11] [12] [13] Tegoprazan, (S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-
1H-benzo[d]imidazole-6-carboxamide, was developed in South Korea
by CJ Healthcare Corp. It is a novel, potent, and highly selective potassium-competitive acid blocker (P-CAB) with a mechanism of action distinct from that of the PPIs. Nonclinical studies have shown that this compound suppresses gastric acid secretion faster and more potently than esomeprazole treated group. 14 The therapeutic potential of tegoprazan may be derived from its ability to accumulate at high concentrations in the canaliculi of gastric parietal cells. Consequently, it is slowly cleared from the gastric glands and exerts its effects independent of acid levels, leading to a strong and sustained effect. 14 Tegoprazan has been demonstrated a strong antisecretory potency and a fast onset of action in several phase I studies. 15 Its suppressive effect on acid secretion reaches a maximum plateau within 0.5-1 hour after administration at a dose of 50, 100 or 200 mg. 15 The food effect on pharmacodynamics and pharmacokinetics study indicated that the efficacy of tegoprazan is independent of food intake. 16 The pharmacodyniamc data of tegoprazan indicate that the 50 and 100 mg doses increase intragastric pH to ≥4 significantly more than the dexlansoprazole 60 mg with evening dosing. 17 In a phase II doseranging study, the proportions of patients with EE who were healed up to week 8 were comparable between tegoprazan (50-200 mg, once daily) and esomeprazole (40 mg, once daily). 18 On the basis of these phase I pharmacodynamics data and phase II dose finding study in EE patients, it was hypothesised that treatment with tegoprazan could produce at least comparable clinical efficacy in healing of oesophagitis and symptom control compared with the treatment of PPIs.
Esomeprazole has been shown to have better acid control than lansoprazole, omeprazole and rabeprazole, 19, 20 and higher oesophagitis healing rates than lansoprazole and omeprazole. 21 Therefore, esomeprazole 40 mg was considered to be the most appropriate comparator to tegoprazan.
The purpose of this phase III study was to verify the non-inferiority of safety and efficacy of tegoprazan 50 and 100 mg to those of esomeprazole 40 mg in patients with EE.
| MATERIALS AND METHODS

| Study design and treatments
Adult patients with endoscopically confirmed EE at screening were eligible for enrolment into the 8-week, double-blind, three-armed, 
| Study protocol
The patients were randomised to receive either tegoprazan or esomeprazole. All randomisation information was securely stored and could be accessed by authorised personnel only. A doubledummy method, using matching tegoprazan and esomeprazole placebo tablets, was employed to ensure that the study was double- severe) using daily diaries.
| Outcome evaluation
The primary endpoint was the proportion of EE patients with healed EE confirmed by endoscopy up to week 8. The secondary endpoints included subjective symptoms, such as changes in RDQ scores, the percentage of days without major symptoms as reported in the patient's diary, GERD-HRQL score, and the proportion of EE patients with healed EE confirmed by endoscopy at week 4.
Safety was assessed by physical examinations and the analysis of adverse events, laboratory test values, ECG findings and vital signs.
The frequency and severity of adverse events and concomitant medications were monitored throughout the study. Treatment-emergent adverse event (TEAE) was defined as an adverse event occurred during treatment, representing a change from baseline. All TEAEs were graded based on severity as severe, moderate or mild by the investigator. A drug-related TEAE was an adverse event that was deemed by the investigator as possibly related or as related to the study drug. A serious TEAE was defined as an adverse event that could cause death, hospitalisation, disability, congenital anomaly or a lifethreatening adverse event.
| Statistical analysis
Based on the results of a phase II study in which the proportion of EE patients showing healed EE up to week 8 was 96.0% for tegoprazan 50 mg, 97.9% for tegoprazan 100 mg, and 96.1% for esomeprazole 40 mg, the sample size in the present study was calculated 100 subjects per treatment group. A power of ≥90% was used to detect non-inferiority of tegoprazan to esomeprazole with a noninferiority margin of 10%.
For the primary endpoint, the proportion of patients with healed EE up to week 8 was calculated in the per protocol set (PPS) population. The non-inferiority of tegoprazan to esomeprazole was tested by comparing the lower bound of two-sided 95% confidence intervals with a non-inferiority margin of 10%. The same analyses were performed for the proportion of patients with healed EE up to week 4. Wilcoxon's rank sum test was performed to compare the change of symptom scores between groups.
Besides the PPS analysis (n = 271), the intention-to-treat (ITT) analysis (n = 300) was also performed for efficacy analysis.
| RESULTS
| Study subjects
Out of the 452 patients enrolled in the study, 302 eligible patients were randomised to receive either tegoprazan (50 mg, n = 100; 100 mg, n = 102) or esomeprazole (n = 100). A total of 286 subjects completed the study (Figure 1 ).
The treatment groups were comparable regarding the baseline characteristics except the history of smoking. EE severity at baseline was similar between treatment groups ( Table 1 ).
The overall compliance rate exceeded 95% in all the treatment groups. The mean compliance rates were 98.1%, 97.9% and 97.1%
in the tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, respectively.
Sixteen patients (5.3%) did not complete the study: five in the tegoprazan 50 mg group, four in the tegoprazan 100 mg group and seven in the esomeprazole group. The details of each treatment group are summarised in the flow chart in Figure 1 .
| Healing rate of EE
In the PPS population, the proportion of patients with healed EE over the 8-week treatment period was 98.9%, 98.9% and 98.9% in the tegoprazan 50 and 100 mg and esomeprazole 40 mg groups, respectively. The lower bound of the two-sided 95% confidence interval of the treatment difference (tegoprazan-esomeprazole) met the prespecified non-inferiority criteria (Table 2 ). Both doses of | 867 tegoprazan were non-inferior to esomeprazole 40 mg (P < 0.0001).
In the ITT analysis, the healing rates up to week 8 were comparable between the tegoprazan (50 and 100 mg) and esomeprazole (40 mg)
groups. There were no statistically significant differences between the treatment groups ( Table 2 ).
In the PPS population, the proportion of patients with healed EE over the 4-week treatment period was 91.3% and 93.4% in the tegoprazan 50 and 100 mg groups, respectively, which were similar to that of the esomeprazole group (94.3%). The healing rate at week 4 in the ITT analysis was 87.9% in the tegoprazan 50 mg group (n = 99), 90.2% in the tegoprazan 100 mg group (n = 102) and 87.9% in the esomeprazole 40 mg group (n = 99). In the ITT analysis, tegoprazan 50 and 100 mg were non-inferior to esomeprazole 40 mg (P = 0.0156 and 0.0026, respectively).
| Symptom response
Patients in all the three treatment groups reported significant improvement in the severity and frequency of heartburn, dyspepsia and regurgitation, which were assessed at weeks 4 and 8 using RDQ scores (P < 0.0001). Mean RDQ severity and frequency scores significantly decreased after the 4-and 8-week treatments with the investigational drugs. There were no significant differences between the treatment groups regarding mean changes in RDQ total scores at either week 4 or 8. Mean reductions in the severity/frequency of heartburn and dyspepsia did not show statistically significant differences between the treatment groups at week 8.
Reductions in the regurgitation severity and frequency were statistically higher in the tegoprazan 50 mg group at week 4 and 8 than in the esomeprazole 40 mg group. However, significant difference (P-value) of regurgitation at baseline was observed between the treatment groups, and the least-squares mean change in the regurgitation score from baseline to week 4 or 8 was analysed
additionally. There was no statistically significant difference between the three treatment groups after adjustment of baseline (Table 3 ).
There was a significant increase in the percentage of days without major symptoms (heartburn and regurgitation) in all the treatment groups, but there were no statistically significant differences between the treatment groups (data not shown). GERD-HRQL total scores over the 4-and 8-week treatment periods reduced significantly in all the treatment groups. The mean reduction in GERD-HRQL scores of the tegoprazan-treated groups was not significantly different from that in the esomeprazole-treated group (Table 4) .
| Tolerability and safety
Three hundred patients received at least one dose of a study medication and were included in the safety analyses. Most TEAEs (136/ 149, 91.3%) were mild in intensity. Two severe TEAEs that were joint injury and breast cancer in the tegoprazan 50 mg group that were "definitely not related" to the investigational drug. There were no severe TEAEs in the tegoprazan and esomeprazole groups. The percentages of patients with more than one TEAE were 28.3%, 23.5% and 30.3% in the tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg groups, respectively (Table 5) . Drug-related TEAEs (≥2%) are shown in Table 6 . Dyspepsia (2.0%) and chest discomfort (2.0%) in the tegoprazan groups, and headache (4.0%) in the esomeprazole group were the most frequently reported drug-related TEAEs (Table 6 ). All the TEAEs disappeared spontaneously without any treatment. The percentage of patients with TEAEs leading to premature discontinuation of treatment was 2.9% in the tegoprazan 50 mg group, 2.9% in the esomeprazole 40 mg group and 3.0% in the tegoprazan 100 mg group. Headache (2% in the esomeprazole 40 mg group) was the most common adverse event that led to discontinuation. The rate of serious TEAEs was 2.0% in the tegoprazan 50 mg group, 2.0% in the tegoprazan 100 mg group and 1.0% in the esomeprazole 40 mg group. All serious TEAEs were considered to be unrelated to the study medication by the investigators. No significant changes in vital signs or ECG findings were observed during the study period. CIs, confidence intervals; ITT, intention-to-treat; PPS, per protocol set.
a Non-inferiority test at the significant level 0.05 (two-sided).
| DISCUSSION
The findings of the current randomised controlled study in 302 patients with EE demonstrated that tegoprazan, when administered at 50 or 100 mg once daily, was non-inferior to esomeprazole 40 mg regarding the healing rate of EE. Both doses of tegoprazan were highly effective in healing EE. Tegoprazan 100 mg did not provide additional clinical benefit over tegoprazan 50 mg. However, we did not observe any superior results of tegoprazan over esomeprazole since the healing rates in all treatment groups were too high to detect any significant differences.
The healing rates after 4 weeks of treatment were also comparable between the treatment groups, and higher than 90% in all treatment groups. ITT analyses of the healing rate after the 4-week treatment demonstrated the non-inferiority of tegoprazan 50 mg to esomeprazole 40 mg.
All these results are consistent with those of a previous phase II dose-ranging study in EE patients. 18 Subgroup analysis according to the baseline LA grade of oesophagitis revealed no significant differences in healing rates between the two doses of tegoprazan and esomeprazole 40 mg at week 4 and 8 (data not shown).
Treatment with tegoprazan also showed high healing rates (100%) in EE patients with LA grade C/D, although the number of those patients was small (n = 3-4/group). In South Korea, most of patients with EE have LA grade A or B. Patients with LA grade C or D are relatively rare. 22, 23 Currently, two P-CABs including tegoprazan have been approved for the treatment of GERD. Revaprazan, the first P-CAB was approved for treating peptic ulcers. 24, 25 The second P-CAB clinically available was vonoprazan, which was recently approved for the treatment of EE in Japan. [26] [27] [28] Tegoprazan was approved in South Korea in July, 2018 for the treatment of EE and NERD, and it became the first P-CAB clinically available for treating NERD. 29, 30 The present study showed that RDQ scores assessing the severity and frequency of regurgitation significantly decreased more in the tegoprazan 50 mg group than in the esomeprazole group (P < 0.05, Wilcoxon's rank sum test). However, there was significant difference in the baseline score at the baseline between treatment groups. We analysed the regurgitation score change from baseline to 4 or 8 week using Least square mean (data now shown), and found that there was no significant difference of the regurgitation score change among the three treatment groups.
Both tegoprazan and esomeprazole were well tolerated in the current study. Two patients in the tegoprazan 50 mg group, two in the tegoprazan 100 mg group and three in the esomeprazole group discontinued treatment because of TEAEs. Dyspepsia and chest | 869 discomfort were drug-related TEAEs with an incidence of ≥2% in the tegoprazan 50 mg group (Table 6 ). Headache was the most frequently reported drug-related TEAE in the esomeprazole 40 mg group, that was the only drug-related TEAE showing a significant difference compared to the other group (P = 0.0196). Diarrhoea was the most frequent TEAE in the tegoprazan 50 and 100 mg groups. However, there was no significant difference in the occurrence rate of diarrhoea between the three treatment groups (P = 0.3093).
Furthermore, there were no newly identified safety signals or any significant changes in vital signs, ECG findings or other safety signals.
Overall, all the treatments were well tolerated. Moreover, the incidences of TEAEs, drug-related TEAEs, serious TEAEs and TEAEs leading to drug discontinuation were similar between the tegoprazan-and esomeprazole-treated groups. The majority (91.3%) of TEAEs were considered mild in severity and not related to the study drug.
In conclusion, once daily administration of tegoprazan 50 or 100 mg shows non-inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg.
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